A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00722358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: BMS-650032
DRUG: Placebo

Sponsor

Bristol-Myers Squibb